Cellectis (NASDAQ:CLLS – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Risk and Volatility
Cellectis has a beta of 3.27, suggesting that its stock price is 227% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cellectis and Achilles Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectis | $29.07 million | 2.34 | -$101.06 million | ($1.30) | -0.94 |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.87 |
Analyst Recommendations
This is a summary of recent ratings and price targets for Cellectis and Achilles Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Cellectis currently has a consensus target price of $7.00, suggesting a potential upside of 471.43%. Achilles Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 177.78%. Given Cellectis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectis is more favorable than Achilles Therapeutics.
Profitability
This table compares Cellectis and Achilles Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectis | -234.39% | -74.55% | -22.65% |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
Institutional & Insider Ownership
63.9% of Cellectis shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Cellectis beats Achilles Therapeutics on 9 of the 13 factors compared between the two stocks.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
